NCT01356849 · Interventional trial
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Overall registry status Completed
Phase 2
Conditions Chronic Kidney Disease, Diabetic Nephropathy
Delaware Valley sites
- Site Reference ID/Investigator# 46224 · Doylestown, PA · Bucks County
First posted
Registry updated
Added to the directory